Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Rare Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CANT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CANT1 Recombinant Protein (Golgi Luminal Domain) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CANT1 Products |
| Gene Delivery | CANT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and calcium-activated functional assays. |
View CANT1 Products |
| Benchmark Ab | Anti-CANT1 Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and Flow Cytometry. |
View CANT1 Products |
| Validator | CANT1 siRNA Set Target-specific knockdown verification in prostate cancer and chondrodysplasia cellular models. |
View CANT1 Products |
| Related Target A | ENTPD1 (CD39) Synergistic purinergic signaling node; critical for comparative nucleotidase selectivity screening. |
View ENTPD1 Products |
| Related Target B | NT5E (CD73) Downstream ecto-nucleotidase in the adenosine immunosuppressive pathway. |
View NT5E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent enzyme activity preservation | HEK293 mammalian expression system guarantees correct folding and post-translational modifications. |
| Cross-family nucleotidase off-target screening | High-purity recombinant ENTPD family proteins available for comprehensive selectivity profiling. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies included in the catalog. |
| Assay noise from endotoxin contamination | Strict endotoxin control (<1.0 EU/µg by LAL method) prevents non-specific cellular activation. |
Live CANT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for calcium-activated nucleotidase therapeutics is expanding. While historically studied in the context of Desbuquois dysplasia (DBQD) mutations, CANT1 has emerged as a high-value oncogenic target. It is heavily overexpressed in aggressive prostate cancers, where it modulates proteoglycan synthesis and tumor cell proliferation. Current R&D focus is shifting from basic biology toward high-throughput screening (HTS) of small-molecule inhibitors and targeted knockdown strategies to disrupt cancer metabolism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Prostate Cancer, Solid Tumors | Enzymatic activity assays requiring highly pure, active recombinant CANT1 protein. |
| RNA Therapeutics (siRNA/ASO) | RNAi Developers | Aggressive Prostate Adenocarcinoma | Sequence-verified siRNA validation pools to confirm target knockdown in vitro. |
| Gene Therapy / Replacement | Orphan Disease Specialists | Desbuquois Dysplasia (DBQD) | Full-length Lentivirus for stable expression and rescue assays in patient-derived fibroblasts. |